Novigenix, Alveolix, and Syntheticus are key players in major European-funded initiatives that harness AI to advance clinical developments in prostate and pancreatic cancer treatment. One project aims to explore the potential of synthetic data to foster the development of AI-driven diagnostic tools, personalized treatments, and predictive health outcomes.
The MYeloid SIGNATUREs (MY-SIGNATURE) project led by Novigenix, a leader in AI-driven healthcare solutions, aims to address the urgent need for robust biomarkers to optimize treatment and overcome resistance to current therapies for prostate cancer, which causes approximately 110,000 fatalities each year in the EU. The project has been approved for a Eurostars grant, with a consortium total budget of €1.75 million, which will support the development of MYELO-SCAN, the world’s first liquid biopsy test designed to predict intratumoral myeloid-derived suppressor cell (MDSC) infiltration in metastatic castration-resistant prostate cancer (mCRPC) patients. Kicking off in October this year, MYELO-SCAN will be ready for clinical validation by Q4 2026 followed by CE-marking. Novigenix will lead the consortium collaboration with the Dutch subsidiary of Crown Bioscience and the “Precision Medicine in Genito-Urinary Cancers” research group led by Niven Mehra, Associate Professor in Medical Oncology at Radboud University and a key opinion leader in immuno-oncology.
Eurostars grant for EU project with Alveolix
Alveolix, with its patented AXBarrier-on-Chip System, a platform enabling advanced safety and efficacy models for pre-clinical testing, is one of the members of the PANC-CKI project which aims to validate CI-CK1i, a new inhibitor targeting casein kinase 1 (CK1) for the treatment of pancreatic cancer patient, needing urgently new treatment options. The consortium has received €4M Eurostars grant. Led by the Czech biotech, CasInvent Pharma, the consortium will conduct Proof-of-Concept studies to generate a data package for initiating IND/CTA studies. Participants employ a completely novel drug development, process synergistically combining cutting-edge technologies including creation of digital twin using AI/ML technologies with rapid screening of drug combination using state-of-the art cancer patient-derived organoids at the University of Bern (Prof. Marianna Kruithof-de Julio). Safety testing will be performed by a new organs-on-chip technology developed by Alveolix (Switzerland).
Joint Undertaking Health Syntheticus
The Synthetic hEalthcare dAta goveRnanCe Hub (SEARCH) consortium, comprising 26 partners from across Europe, is partnering with Swiss startup Syntheticus to accelerate healthcare innovation by generating FAIRified synthetic data for use in AI/ML models. Funded under the Innovative Health Initiative Joint Undertaking (IHI JU), SEARCH boasts an initial budget of over €13.9 million. Founded in 2021, Syntheticus® empowers organizations (B2B) and governments (B2G) to enable the full potential of AI through safe synthetic data and will thus play a key role in SEARCH by leveraging its cutting-edge solutions to unlock the full potential of synthetic data, ensuring privacy, compliance, and scalability for the healthcare industry. The startup will contribute its expertise in Privacy-Enhancing Technologies (PETs), including Generative AI and Differential Privacy. This will support the creation of synthetic datasets that replicate real-world healthcare data while preserving patient privacy. These datasets will enable healthcare providers, researchers, and institutions to develop AI-driven tools for diagnostics, personalized treatments, and predictive health outcomes.
(Press release/RAN)
Image vy FreePik
0Comments
The new Swiss Venture Capital Report was published on 26 January. It analyses 304 financing rounds closed in 2020 and includes further article such as an interview with Michael Hengartner, President of the ETH Board, and a list of Swiss "soonicorns". 
Please login or sign up to comment.
Commenting guidelines